- Previous Close
20.80 - Open
20.80 - Bid 20.60 x --
- Ask 20.80 x --
- Day's Range
20.00 - 21.80 - 52 Week Range
17.84 - 140.15 - Volume
16,456 - Avg. Volume
17,027 - Market Cap (intraday)
54.762M - Beta (5Y Monthly) 1.65
- PE Ratio (TTM)
0.01 - EPS (TTM)
2,210.02 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
303.00
ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2ion Biotechnologies ApS, researches and develops preventive and therapeutic vaccine products in the Nordics and internationally. The company's lead asset is ES2B-C001, a therapeutic vaccine for breast cancer that targets the human epidermal growth factor receptor 2 receptor. It is also developing ES2B-I002, a cytomegalovirus vaccine candidate to treat infectious diseases. In addition, the company out licenses its ExpreS2 platform to research institutes and pharmaceutical companies. Further, it sells ExpreS2 test kits and reagents for research purposes or diagnostic applications. The company has collaboration agreement with University of Oxford for the development of vaccine for malaria; and Evaxion Biotech A/S for development of cytomegalovirus vaccine, as well as partnership agreement with Copenhagen University to develop vaccine for Influenza. The company operates an online store. ExpreS2ion Biotech Holding AB (publ) was incorporated in 2015 is based in Helsingborg, Sweden.
www.expres2ionbio.comRecent News: EXPRS2.ST
View MorePerformance Overview: EXPRS2.ST
Trailing total returns as of 12/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXPRS2.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXPRS2.ST
View MoreValuation Measures
Market Cap
54.76M
Enterprise Value
-21.28M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.28
Price/Book (mrq)
0.79
Enterprise Value/Revenue
4.38
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-46.23%
Return on Equity (ttm)
-58.22%
Revenue (ttm)
8.1M
Net Income Avi to Common (ttm)
-45.37M
Diluted EPS (ttm)
2,210.02
Balance Sheet and Cash Flow
Total Cash (mrq)
68.55M
Total Debt/Equity (mrq)
3.70%
Levered Free Cash Flow (ttm)
-16.14M